Affiliations: [a] Department of Molecular Biology and Genetics, Uskudar University, Uskudar, Istanbul, Turkey
| [b] Istanbul Protein Research-Application and Inovation Center (PROMER), Uskudar University, Uskudar, Istanbul, Turkey
| [c] Department of Bioengineering, Uskudar University, Uskudar, Istanbul, Turkey
Correspondence:
[*]
Corresponding author: Vildan Enisoğlu Atalay, Department of Molecular Biology and Genetics, Uskudar University, 34662, Uskudar, Istanbul, Turkey. E-mail: [email protected].
Abstract: Cyclin-dependent kinases (CDKs) are commonly known by their role in cell cycle regulation which affects cancer mechanism. In many cancer types, CDKs show extreme activity or CDK inhibiting proteins are dysfunctional. Specifically, CDK2 plays an indispensable role in cell division especially in the G1/S phase and DNA damage repair. Therefore, it is important to find new potential CDK2 inhibitors. In this study, ligand-based drug design is used to design new potential CDK2 inhibitors. Y8 L ligand is obtained from the X-ray crystal structure of human CDK2 (PDB ID: 2XNB) (www.pdb.org) and used as a structure model. By adding hydrophilic and hydrophobic groups to the structure, a training set of 36 molecules is generated. Each molecule examined with Spartan’14 and optimized structures are used for docking to CDK2 structure by AutoDock and AutoDock Vina programs. Ligand-amino acid interactions are analysed with Discovery Studio Visualizer. Van der Waals, Pi-Pi T-shaped, alkyl, pi-alkyl, conventional hydrogen bond and carbon-hydrogen bond interactions are observed. By docking results and viewed interactions, some molecules are identified and discussed as potential CDK2 inhibitors. Additionally, 8 different QSAR descriptors obtained from Spartan’14, Preadmet and ALOGPS 2.1 programs are investigated with multiple linear regulation (MLR) analysis with SPSS program for their impact on affinity value.
Keywords: CDK2, docking, ligand-based drug design, MLR, Y8 L ligand
